Natural Capsules Reports Divergent Financials for FY26

Natural Capsules posted a standalone net profit of ₹11.21 crore for the fiscal year ended March 2026, with Q4 FY26 profit at ₹5.52 crore. However, on a consolidated basis, the company reported a net loss of ₹24.66 crore for FY26, with Q4 FY26 loss at ₹4.98 crore.

Key Financial Highlights

Natural Capsules Limited announced its audited financial results for the fourth quarter and full fiscal year 2026. Standalone operations showed a profit of ₹11.21 crore for FY26 on revenues of ₹173.77 crore. In contrast, consolidated results for the same period reveal a net loss of ₹24.66 crore, with revenues at ₹187.20 crore.

The company also addressed operational disruptions, noting a temporary shutdown of a manufacturing unit from December 26, 2025, to January 30, 2026, due to regulatory reasons. Operations have since resumed.

Impact of Subsidiaries on Performance

The significant difference between standalone profitability and consolidated losses highlights the impact of subsidiaries on Natural Capsules' overall financial health. Investors are focusing on the performance of the API segment, which reported a substantial loss of ₹31.33 crore for FY26. This segment continues to be a drag on overall profitability.

The temporary manufacturing shutdown, though resolved, underscores the importance of regulatory compliance and operational stability. The re-appointment of a Whole-time Director and a new Company Secretary indicate efforts towards leadership continuity and governance.

Business Background and Recent Changes

Natural Capsules operates in the pharmaceutical sector, manufacturing capsules and Active Pharmaceutical Ingredients (APIs). The company's consolidated performance has historically been influenced by its subsidiary, Natural Biogenex, which handles the API business.

With operations resumed and leadership in place, the company aims to improve its consolidated performance by turning around the API segment. The recent allotment of 25,000 equity shares under ESOP 2025 has slightly increased the paid-up share capital to ₹10.41 crore.

Key Risks to Monitor

The substantial and ongoing losses in the API segment pose a significant risk to the company's consolidated financial performance and investor returns. Future regulatory compliance issues could also lead to further operational disruptions and impact profitability.

Performance Metrics (FY26)

• Standalone Profit: ₹11.21 crore
• Consolidated Loss: ₹-24.66 crore
• API Segment Loss: ₹-31.33 crore
• Manufacturing Unit Shutdown: December 26, 2025 – January 30, 2026

Future Focus

Investors should closely monitor the financial performance of the API segment in upcoming quarters. The company's ability to manage operational risks and ensure consistent regulatory compliance will be crucial for improving consolidated results.